TMS Co., Ltd. (4891.T)
Tokyo · JPY · Healthcare · Biotechnology
¥145 (+4.32%) as of
Key statistics
- Market cap
- 6.72B
- Forward P/E
- -4.53
- EPS (TTM)
- -15.64
- Dividend yield
- 0.00%
- 52-week range
- 92.00 – 165.00
- Beta
- 0.38
- Profit margin
- 0.00%
- Analyst target
- ¥620
- Volume
- 679.60k
About TMS Co., Ltd.
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Fuchu, Japan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.